• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

阿尔茨海默病的神经化学

The neurochemistry of Alzheimer's disease.

作者信息

Engelborghs S, De Deyn P P

机构信息

Department of Neurology, A.Z. Middelheim, Antwerp.

出版信息

Acta Neurol Belg. 1997 Jun;97(2):67-84.

PMID:9246374
Abstract

This paper gives a review of the neurochemical alterations that characterize Alzheimer's disease. The quantitative distribution of each compound or group of compounds over the central nervous system and their concentrations in the cerebrospinal fluid as well as receptor interactions and densities are discussed. Where possible, these neurochemical alterations are correlated with cognitive and noncognitive symptoms. A degeneration of the cholinergic nucleus basalis of Meynert characterizes Alzheimer's disease and results in neocortical cholinergic deficits correlating with cognitive impairment. Catecholaminergic changes include prominent cell loss of the noradrenergic locus coeruleus leading to decreased norepinephrine concentrations in cerebrospinal fluid and several cortical and subcortical areas. Modest, but identical trends are reported for epinephrine and dopamine. The former alterations are correlated with depression and psychosis in Alzheimer's disease. The serotonergic nucleus raphe dorsalis shows evidence of degeneration, causing a decreased serotonin content of the neocortex and the cerebrospinal fluid, which is correlated with both cognitive and noncognitive symptomatology. Several-often less understood-changes of amino acids and neuropeptides will be reviewed. Finally, the neurochemical aspects of cytokine-mediated inflammatory reactions and of oxidative stress in the physiopathology of Alzheimer's disease are reviewed.

摘要

本文综述了阿尔茨海默病的神经化学改变。文中讨论了每种化合物或化合物组在中枢神经系统中的定量分布及其在脑脊液中的浓度,以及受体相互作用和密度。在可能的情况下,这些神经化学改变与认知和非认知症状相关联。Meynert基底核胆碱能神经元的退化是阿尔茨海默病的特征,导致新皮质胆碱能缺陷与认知障碍相关。儿茶酚胺能变化包括去甲肾上腺素能蓝斑核显著的细胞丢失,导致脑脊液以及几个皮质和皮质下区域的去甲肾上腺素浓度降低。肾上腺素和多巴胺也有适度但相同的变化趋势。前者的改变与阿尔茨海默病中的抑郁和精神病相关。5-羟色胺能背侧中缝核显示出退化迹象,导致新皮质和脑脊液中的5-羟色胺含量降低,这与认知和非认知症状学均相关。将对几种通常了解较少的氨基酸和神经肽变化进行综述。最后,综述了细胞因子介导的炎症反应和氧化应激在阿尔茨海默病生理病理学中的神经化学方面。

相似文献

1
The neurochemistry of Alzheimer's disease.阿尔茨海默病的神经化学
Acta Neurol Belg. 1997 Jun;97(2):67-84.
2
Galanin immunoreactivity is increased in the nucleus basalis of Meynert in Alzheimer's disease.
Ann Neurol. 1990 Aug;28(2):157-61. doi: 10.1002/ana.410280207.
3
Neurotransmitters and neuropeptides in Alzheimer's disease.
Psychiatr Clin North Am. 1991 Jun;14(2):421-42.
4
[Neurotransmitter anomalies in Alzheimer's disease].[阿尔茨海默病中的神经递质异常]
Rev Neurol (Paris). 1984;140(10):539-52.
5
[Neurotransmitters in Alzheimer's disease].
Ugeskr Laeger. 1990 Jul 23;152(30):2165-8.
6
[Neuromodulators and Alzheimer's disease].
Encephale. 1988 Sep-Oct;14(5):345-51.
7
Neurotransmitter deficits in Alzheimer's disease and in other dementing disorders.阿尔茨海默病及其他痴呆症中的神经递质缺陷。
Hum Neurobiol. 1986;5(3):147-58.
8
Analysis of cholinergic markers, biogenic amines, and amino acids in the CNS of two APP overexpression mouse models.两种APP过表达小鼠模型中枢神经系统中胆碱能标志物、生物胺和氨基酸的分析
Neurochem Int. 2005 Apr;46(5):409-22. doi: 10.1016/j.neuint.2004.11.005. Epub 2005 Jan 17.
9
Neurochemical studies of early-onset Alzheimer's disease. Possible influence on treatment.
N Engl J Med. 1985 Jul 4;313(1):7-11. doi: 10.1056/NEJM198507043130102.
10
[Studies of cerebrospinal fluid diagnosis in Alzheimer's disease: a review of the literature and of current developments].[阿尔茨海默病的脑脊液诊断研究:文献综述与当前进展]
Tijdschr Gerontol Geriatr. 1992 Dec;23(6):212-6.

引用本文的文献

1
Gene expression of serotonergic markers in peripheral blood mononuclear cells of patients with late-onset Alzheimer's disease.迟发性阿尔茨海默病患者外周血单个核细胞中血清素能标志物的基因表达
Heliyon. 2020 Aug 24;6(8):e04716. doi: 10.1016/j.heliyon.2020.e04716. eCollection 2020 Aug.
2
Neuroprotective effects of multifaceted hybrid agents targeting MAO, cholinesterase, iron and β-amyloid in ageing and Alzheimer's disease.针对衰老和阿尔茨海默病中MAO、胆碱酯酶、铁和β-淀粉样蛋白的多方面混合制剂的神经保护作用
Br J Pharmacol. 2016 Jul;173(13):2080-94. doi: 10.1111/bph.13318. Epub 2015 Dec 1.
3
Ultrastructural Analysis of Chlamydia Pneumoniae in the Alzheimer's Brain.
阿尔茨海默病大脑中肺炎衣原体的超微结构分析
Pathogenesis (Amst). 1999;1(3):201-211.
4
MHP-133, a drug with multiple CNS targets: potential for neuroprotection and enhanced cognition.MHP - 133,一种具有多种中枢神经系统靶点的药物:具有神经保护和增强认知的潜力。
Neurochem Res. 2007 Jul;32(7):1224-37. doi: 10.1007/s11064-007-9294-0. Epub 2007 Apr 3.
5
Drug-induced cognition disorders in the elderly: incidence, prevention and management.老年人药物性认知障碍:发病率、预防与管理
Drug Saf. 1999 Aug;21(2):101-22. doi: 10.2165/00002018-199921020-00004.
6
Mapping the active site in vasoactive intestinal peptide to a core of four amino acids: neuroprotective drug design.将血管活性肠肽中的活性位点定位到四个氨基酸的核心区域:神经保护药物设计。
Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):4143-8. doi: 10.1073/pnas.96.7.4143.